首页 | 本学科首页   官方微博 | 高级检索  
     

阿德福韦酯耐药慢性乙型肝炎患者HBsAg变异分析
引用本文:杨松,李玥,王笑梅,欧蔚妮,邢卉春,成军. 阿德福韦酯耐药慢性乙型肝炎患者HBsAg变异分析[J]. 中华实验和临床感染病杂志(电子版), 2018, 12(3): 225-229. DOI: 10.3877/cma.j.issn.1674-1358.2018.03.005
作者姓名:杨松  李玥  王笑梅  欧蔚妮  邢卉春  成军
作者单位:1. 100015 北京,首都医科大学附属北京地坛医院肝病三科
基金项目:北京市卫生系统高层次卫生技术人才队伍建设专项经费(No.2016-108); 北京市医院管理局扬帆计划项目(肝炎专业)(No. ZYLX201402); 登峰计划项目(肝病专业)(No. DFL20151701)
摘    要:目的探讨阿德福韦酯耐药慢性乙型肝炎患者相关S抗原变异、疫苗逃逸相关变异以及部分已知特异性T细胞表位变异情况。 方法收集2007年12月至2011年9月于首都医科大学附属北京地坛医院收治的阿德福韦酯治疗失败的慢性乙型肝炎患者70例,并随机选择ADV治疗非耐药患者70例作为对照。采用PCR产物直接测序法获得患者HBV反转录酶区与S抗原序列。应用PCR产物直接测序法与焦磷酸测序法明确阿德福韦酯耐药情况。比较阿德福韦酯耐药患者与无阿德福韦酯耐药患者耐药相关S抗原变异、疫苗逃逸相关变异以及HBV特异性T细胞表位变异情况。 结果ADV耐药组与对照组患者人口学等指标差异无统计学意义。本组患者中42例rtA181T耐药变异关联的HBsAg变异均为sW172*。在rtA181T/ sW172*变异患者体内,该变异株在病毒准种中所占平均比率为(42.6 ± 22.1)%(12.2%~100%)。与非ADV耐药组患者相比,ADV耐药组患者发生HBsAg疫苗逃逸变异(χ2 = 12.8736、P = 0.0003)以及T细胞抗原表位变异(χ2 = 4.8344、P = 0.0279)几率显著升高。 结论我国ADV耐药患者rtA181T变异关联的HBsAg变异主要为sW172*变异,HBsAg抗原疫苗逃逸变异以及T细胞抗原表位变异与ADV耐药相互影响,相关机制尚待进一步研究。

关 键 词:肝炎,乙型,慢性  肝炎病毒,乙型  阿德福韦酯  肝炎病毒表面抗原,乙型  
收稿时间:2017-09-27

HBsAg mutations in patients with chronic hepatitis B undergoing adefovir dipivoxil resistance
Song Yang,Yue Li,Xiaomei Wang,Weini Ou,Huichun Xing,Jun Cheng. HBsAg mutations in patients with chronic hepatitis B undergoing adefovir dipivoxil resistance[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Version), 2018, 12(3): 225-229. DOI: 10.3877/cma.j.issn.1674-1358.2018.03.005
Authors:Song Yang  Yue Li  Xiaomei Wang  Weini Ou  Huichun Xing  Jun Cheng
Affiliation:1. Division 3 of Center of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing 00015, China
Abstract:ObjectiveTo investigate adefovir dipivoxil (ADV) resistant mutation related HBsAg mutation, vaccine escape mutation and T cell epitope mutations in Chinese patients with chronic hepatitis B (CHB) who underwent adefovir resistance. MethodsSeventy CHB patients who underwent ADV resistance from December 2007 to September 2011 in Beijing Ditan Hospital, Capital Medical Unversity were enrolled. While 70 ADV treated patients without ADV resistance were randomly selected as control group. HBV Rt/S ORF were sequenced with PCR product Sanger sequencing and pyrosequencing. ADV resistant mutation related HBsAg mutation, vaccine escape mutation and T cell epitope mutations were compared between ADV treated CHB patients with and without ADV resistance. ResultsTotal of 70 ADV resistant patients with CHB were enrolled, while 70 ADV treated CHB patients without ADV resistance were set as control. Baseline characteristics were comparable between the two groups. All 42 rtA181T mutations were related to sW172* mutations. Mean ratio of rtA181T/sW172* mutations in quasispecies was (42.6 ± 22.1)% (12.2%-100%). More patients in resistance group showed vaccine escape mutation (χ2 = 12.8736, P = 0.0003) and T cell epitope mutations (χ2 = 4.8344, P = 0.0279) than control group. ConclusionsIn Chinese patients with CHB, rtA181T is mainly related to sW172* mutations. ADV resistance is related to vaccine escape mutation and T cell epitope mutations. Further studies should focus on the possible mechanism.
Keywords:Chronic hepatitis B  Hepatitis B virus  Adefovir dipivoxil  Hepatitis B surface antigen  
本文献已被 CNKI 等数据库收录!
点击此处可从《中华实验和临床感染病杂志(电子版)》浏览原始摘要信息
点击此处可从《中华实验和临床感染病杂志(电子版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号